A computational algorithm to analyze Big Data obtained from tumor samples to better understand and treat cancer has been developed by researchers.
A growing problem in cancer research is figuring out how to analyze the many kinds of big genomic data for different cancers. The overwhelming quantity and complexity of the data has created an analysis bottleneck that has slowed the translation of the knowledge within the data to the clinic. University of Hawaii Cancer Center researchers developed a computational algorithm to analyze "Big Data" obtained from tumor samples to better understand and treat cancer.
‘A computational algorithm to analyze "Big Data" obtained from tumor samples to better understand and treat cancer has been developed by researchers.’
Gordon Okimoto, Co-Director of Biostatistics and Informatics Shared Resource at the UH Cancer Center, said, "We have figured out a way to mine these data for the benefit of cancer patients." Okimoto and collaborators developed a computational algorithm called the Joint Analysis of Many Matrices by ITeration (JAMMIT). JAMMIT uses advanced mathematics to identify different patterns across multiple molecular data types such as gene expression and genetic mutations that when taken together accurately predicts what treatments would be best for a given cancer patient.
"The algorithm could accelerate the approval of powerful treatments for many cancers, improve clinical outcomes, and reduce costs for treating cancer. I believe this discovery can open a path to more precision medicine clinical trials that could be initiated and run locally in Hawaii," said Randall Holcombe, incoming Director of the UH Cancer Center.
The findings published in Biodata Mining highlight JAMMIT analysis of ovarian and liver cancer data pulled from private research labs and public databases such as The Cancer Genome Atlas (TCGA), a National Cancer Institute data archive. The analysis identified small sets of genes that accurately predict which patients would benefit most from chemotherapy. These same signatures also suggest that many of the ovarian and liver cancer patients studied would benefit from combining chemotherapy with immunotherapy.
Okimoto plans on analyzing the data for dozens of more cancers.
Advertisement
Okimoto and Thomas Wenska started SNR Analytics, Inc. The start-up is focused on securing the IP and funding for the development of a computational pipeline based on the JAMMIT algorithm for the discovery of predictive gene signatures for cancer and other complex diseases.
Advertisement